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1. Introduction {#ehf212629-sec-0004}
===============

Continuous flow left ventricular assist devices (cf‐LVADs) have become an important modality in the treatment of end‐stage heart failure (HF) as a bridge to transplantation (BTT), bridge to candidacy, or as destination therapy. This has led to a significant improvement of the quality of life and overall survival of patients once all other therapeutic options have been exhausted.[1](#ehf212629-bib-0001){ref-type="ref"}

A small percentage of these patients experience significant myocardial recovery under LVAD support and can therefore undergo LVAD explantation, defined as actual bridge to recovery (BTR).[1](#ehf212629-bib-0001){ref-type="ref"} The eighth Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) annual report and the second European Registry for Patients with Mechanical Circulatory Support (EUROMACS) report, reported that 1--2% of the patients implanted with cf‐LVADs recovered, allowing successful LVAD explantation.[1](#ehf212629-bib-0001){ref-type="ref"}, [2](#ehf212629-bib-0002){ref-type="ref"} Similarly, in a pooled HeartMate II cohort with 1108 patients enrolled, the rate of myocardial recovery was 1.8%.[3](#ehf212629-bib-0003){ref-type="ref"}

Several case series and small cohort studies report patients having sufficient recovery of left ventricle (LV) function that allowed LVAD explantation. These studies show higher rates of myocardial recovery after LVAD explantation and survival ranging from 78.3% to 100%, with varying rates of HF recurrence.[4](#ehf212629-bib-0004){ref-type="ref"}, [5](#ehf212629-bib-0005){ref-type="ref"}, [6](#ehf212629-bib-0006){ref-type="ref"}, [7](#ehf212629-bib-0007){ref-type="ref"}, [8](#ehf212629-bib-0008){ref-type="ref"}

These studies report encouraging survival outcomes; however, much remains unknown concerning adverse events (AEs) and HF management after explantation and most studies are based on single‐centre experiences. Little is known about long‐term outcomes and AEs, such as ventricular tachycardia or thromboembolic complications, given the fact that the inflow cannula is not (always) extracted and data about its management are usually lacking. Furthermore, the follow‐up of these patients is limited, and details on specific medication are lacking and not consistent because of a small number of patients. There is no evidence‐based knowledge regarding the long‐term treatment of these patients in case of recurrence of HF or other complications. Such inconsistencies prompt a need for a complete long‐term follow‐up in these patients, with a special emphasis on chronic medication, AEs, and longer‐term survival after successful LVAD explantation.

1.1. Objectives {#ehf212629-sec-0005}
---------------

The aim of the study is to evaluate long‐term outcomes and patient management after a successful LVAD termination due to the recovery, including survival, complications, relapse of HF, and specific medical treatments.

2. Methods {#ehf212629-sec-0006}
==========

2.1. Study design {#ehf212629-sec-0007}
-----------------

A retrospective study was conducted in all patients in whom an LVAD was successfully explanted after myocardial recovery as registered in the EUROMACS.[2](#ehf212629-bib-0002){ref-type="ref"}, [9](#ehf212629-bib-0009){ref-type="ref"} Inclusion criteria were successful explantation of a cf‐LVAD (as a stand‐alone VAD system, not right VAD) as captured in the follow‐up of EUROMACS. Exclusion criteria included an explantation due to any other reason than myocardial recovery (e.g. infection and device malfunction) or patients aged \<18 years.

2.2. Data collection {#ehf212629-sec-0008}
--------------------

From January 2011 until March 2018, a total of 45 patients in the EUROMACS registry were identified as being successfully explanted after myocardial recovery, from now on named recovery patients. Baseline characteristics before LVAD implantation including age, sex, aetiology of HF, pre‐operative condition and co‐morbidities, electrocardiogram, echocardiogram, and blood chemistry values were collected for adult patients in EUROMACS. Furthermore, perioperative data on device strategy, device type, concomitant surgical procedures, and cardiopulmonary bypass (CPB) time, time in operating room, intensive care unit, and hospital stay were retrieved. Finally, time on LVAD and type and number of AEs and hospitalizations were collected from the follow‐up.

Subsequently, a detailed questionnaire was sent to involved centres to attain the follow‐up of these patients after LVAD explantation. These data are currently not captured in the EUROMACS registry. Because data entry into EUROMACS is anonymized for external reviewers, the executive director (T. M. M. H. d. B.) approached the centres asking to provide the follow‐up of these patients. Data collected included the primary outcome: survival, heart transplantation (HTx), reimplantation of LVAD, and data on re‐hospitalizations due to HF. Secondary outcomes consisted of the following parameters: presence of the inflow cannula, the occurrence of cerebrovascular accidents, New York Heart Association (NYHA) class at last follow‐up, oral anticoagulation, and HF medication. Finally, data of electrocardiogram, echocardiography, and blood chemistry values were requested.

2.3. Statistical analysis {#ehf212629-sec-0009}
-------------------------

Continuous parameters are expressed as mean and confidence interval or median and range or inter‐quartile range. Categorical parameters are expressed as number and percentage. For categorical parameters, *χ* ^2^ test and Fisher\'s exact test were applied as appropriate. For continuous parameters, Student\'s *t*‐test and Wilcoxon rank‐sum test were used. A comparison of baseline characteristics was performed to assess differences in patients with VAD explantation and without VAD explantation. Furthermore, baseline characteristics of patients whose LVAD was explanted with and without follow‐up were compared to assess a potential reporting bias. Finally, a Kaplan--Meier curve was constructed to evaluate freedom of the composite endpoint of death, HTx, LVAD reimplantation, or relapse of HF ≥ NYHA III after LVAD explantation. Statistical analysis was performed using SPSS, Version 25.0 for Windows (IBM Inc., Armonk, NY, USA).

3. Results {#ehf212629-sec-0010}
==========

3.1. Baseline characteristics {#ehf212629-sec-0011}
-----------------------------

A total of 45 patients in whom the LVAD was explanted because of myocardial recovery were identified in the EUROMACS registry, representing 1.4% of the patients registered at the time. A complete follow‐up of 28 (62.2%) recovery patients after explantation was obtained. In these patients, median age at implantation was 43 years (range 29--52) and 23 patients (82.1%) were male (*Table* [1](#ehf212629-tbl-0001){ref-type="table"} *A*). Predominant aetiologies of HF were myocarditis in nine (32.1%) patients and dilated cardiomyopathy in 10 (35.7%) patients. Most patients had a short history of cardiac disease, with 14 (50%) patients having had their first cardiac diagnosis less than 1 month prior to the LVAD implantation and 20 (71.4%) within 1 year prior to the implantation. Patients were almost evenly distributed over INTERMACS Patient Profiles I to III, only three patients had INTERMACS Patient Profile IV--V. Median LVEF was 18% (inter‐quartile range: 10--20%), whereas five patients exhibited greater than or equal to moderate mitral regurgitation. At the time of implant, 23 (82.1%) patients had inotropic support and 14 patients (50%) experienced any form of mechanical circulatory support by either extracorporeal life support or an intra‐aortic balloon pump. There were, apart from mitral regurgitation, no significant differences between patients with or without an obtained follow‐up after LVAD explantation (*Table* [1](#ehf212629-tbl-0001){ref-type="table"} *A*).

###### 

A: Baseline characteristics of all patients with left ventricular assist device explantation due to myocardial recovery with and without follow‐up after explantation

                                        With follow‐up (28)    No follow‐up (17)    *P*‐value
  ------------------------------------ --------------------- --------------------- -----------
  Age (years)                               43 (29--52)           53 (41--65)         0.053
  Male                                       23 (82.1)             13 (76.5)          0.711
  BMI(kg/m^2^)                          26.9 \[25.1--28.6\]   25.7 \[23.2--28.2\]     0.182
  BSA(m^2^)                             2.02 \[1.92--2.12\]   1.98 \[1.87--2.10\]     0.395
  Aetiology                                                                           0.579
  Myocarditis                                9 (32.1)              3 (17.6)        
  Dilated cardiomyopathy                     10 (35.7)             4 (23.5)        
  Ischaemic cardiomyopathy                   4 (14.3)              5 (27.1)        
  Peripartum                                  1 (3.6)               1 (5.9)        
  Valvular heart disease                      2 (7.1)              2 (11.8)        
  Hypertrophic cardiomyopathy                  0 (0)                1 (5.9)        
  Toxic                                       1 (3.6)                0 (0)         
  Restrictive cardiomyopathy                   0 (0)                 0 (0)         
  Congenital heart disease                     0 (0)                 0 (0)         
  Other/unknown                               1 (3.6)               1 (5.9)        
  Time since first cardiac diagnosis                                                  0.453
  \<1 month                                   14 (50)              6 (35.3)        
  1 month--1 year                            6 (21.4)              5 (29.4)        
  1 year or more                             4 (14.3)              5 (29.4)        
  Unknown                                    4 (14.3)               1 (5.9)        
  Current ICD in place                        2 (7.1)              2 (11.8)           1.000
  INTERMACS profiles                                                                  0.918
  INTERMACS 1                                8 (28.6)              6 (35.3)        
  INTERMACS 2                                9 (32.1)              6 (35.3)        
  INTERMACS 3                                8 (28.6)              3 (17.6)        
  INTERMACS 4--5                             3 (10.7)              2 (11.8)        
  INTERMACS 6--7                               0 (0)                 0 (0)         
  Echocardiography                                                                 
  LVEF (%)                                  18 (10--20)           15 (15--20)         0.612
  LVEDD (mm)                                68 (63--70)           66 (62--73)         0.771
  Aortic regurgitation ≥ moderate                1                     0              1.000
  Mitral regurgitation ≥ moderate                4                     9              0.038
  ECG rhythm                                                                          0.389
  Sinus                                      18 (64.3)             14 (82.4)       
  Atrial fibrillation/flutter                5 (17.9)              3 (17.6)        
  Paced                                       1 (3.6)                0 (0)         
  Other/unknown                              4 (14.3)                0 (0)         
  Heart rate (b.p.m.)                      97 (89--121)          98 (74--111)         0.455
  Blood pressure (mmHg)                                                            
  Systolic                                 105 (92--115)         106 (94--114)        0.919
  Diastolic                                 61 (60--70)           67 (50--70)         0.942
  Mean arterial pressure                    74 (72--84)           78 (70--82)         0.965
  Diabetes                                    2 (7.1)                0 (0)            0.519
  Inotropic support                                                                
  Intravenous inotropes                      23 (82.1)             14 (82.4)          0.333
  1--2 inotropes                             18 (64.3)             8 (47.1)        
  ≥3 inotropes                               5 (17.9)              6 (35.3)        
  IABP                                       4 (14.3)              3 (17.6)           1.000
  ECLS                                       10 (35.7)             7 (41.2)           0.715
  Mechanical ventilation                     8 (28.6)              6 (35.3)           0.637
  Blood chemistry                                                                  
  Creatinine (μmol/L)                      105 (79--114)         114 (91--141)        0.142
  ALAT (U/L)                               76 (39--177)          46 (34--520)         0.892
  ASAT (U/L)                               180 (42--592)         73 (27--184)         0.147
  LDH (U/L)                               469 (308--1189)       407 (338--992)        0.859
  Total bilirubin (mg/dL)                 1.5 (0.8--2.5)        1.5 (0.8--2.1)        0.525
  Haemoglobin (g/dL)                     11.8 (10.2--13.4)     10.9 (10.4--13.7)      0.971
  White blood cell count (× 10^9^/L)     10.6 (9.3--14.3)      10.7 (8.7--13.4)       0.819
  Thrombocytes (× 10^9^/L)                 164 (75--241)        191 (104--266)        0.479

ALAT, alanine aminotransaminase; ASAT, aspartate transaminase; BMI, body mass index; BSA, body surface area; ECG, electrocardiogram; ECLS, extracorporeal life support; IABP, intra‐aortic balloon pump; ICD, implantable cardioverter‐defibrillator; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LDH, lactate dehydrogenase; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction.

Values are median (inter‐quartile range), mean \[confidence interval\], or *n* (%).

###### 

B: Baseline characteristics of all patients with and without left ventricular assist device explantation due to myocardial recovery

                                                                 Explanted           Not explanted     *P*‐value
  -------------------------------------------------------- --------------------- --------------------- -----------
  Age (years)                                                   44 (32--54)           56 (47--62)      \<0.001
  Male                                                           36 (80.0)            2568 (83.6)      0.542
  BMI(kg/m^2^)                                              26.4 \[25.0--27.8\]   26.1 \[26.0--26.3\]  0.691
  BSA(m^2^)                                                 2.00 \[1.93--2.08\]   1.97 \[1.96--1.98\]  0.313
  Aetiology                                                                                            \<0.001
  Myocarditis                                                    12 (26.7)             125 (4.1)       
  Dilated cardiomyopathy                                         14 (31.1)            995 (32.4)       
  Ischaemic cardiomyopathy                                        9 (20)              1285 (41.8)      
  Peripartum                                                      2 (4.4)              14 (0.5)        
  Valvular heart disease                                          4 (8.9)              45 (1.5)        
  Hypertrophic cardiomyopathy                                     1 (2.2)              30 (1.0)        
  Toxic                                                           1 (2.2)              51 (1.7)        
  Restrictive cardiomyopathy                                       0 (0)               20 (0.7)        
  Congenital heart disease                                         0 (0)               28 (0.9)        
  Other/unknown                                                   2 (4.4)             480 (15.6)       
  Time since first cardiac diagnosis                                                                   \<0.001
  \<1 month                                                      20 (44.4)            302 (11.1)       
  1 month--1 year                                                11 (24.4)            356 (13.1)       
  1 year or more                                                  9 (20)              1857 (68.4)      
  Unknown                                                        5 (11.1)              198 (7.3)       
  Current ICD in place                                          1633 (61.4)             4 (8.9)        \<0.001
  INTERMACS profiles                                                                                   0.01
  INTERMACS 1                                                    14 (31.1)            412 (13.4)       
  INTERMACS 2                                                    15 (33.3)            996 (32.4)       
  INTERMACS 3                                                    11 (24.4)            781 (25.4)       
  INTERMACS 4--5                                                 5 (11.1)             637 (21.6)       
  INTERMACS 6--7                                                  0 (0.0)              123 (4.2)       
  Echocardiography                                                                                     
  LVEF (%)                                                      17 (15--19)           19 (19--19)      0.125
  LVEDD (mm)                                                 65.6 (62.2--69.0)     71.3 (70.1--72.6)   0.270
  Aortic regurgitation greater than or equal to moderate          1 (3.4)              92 (3.8)        1.000
  Mitral regurgitation greater than or equal to moderate         13 (38.2)            1221 (50.9)      0.141
  ECG rhythm                                                                                           0.005
  Sinus                                                          32 (71.1)            1359 (51.5)      
  Atrial fibrillation/flutter                                    8 (17.8)             424 (16.1)       
  Paced                                                           1 (2.2)             663 (25.1)       
  Other/unknown                                                   4 (8.9)              192 (7.3)       
  Heart rate (b.p.m.)                                          100 (92--107)          87 (86--87)      \<0.001
  Blood pressure (mmHg)                                                                                
  Systolic                                                    106 (100--112)        100 (100--102)     0.048
  Diastolic                                                     64 (59--69)           65 (64--65)      0.725
  Mean arterial pressure                                        78 (73--83)           77 (76--77)      0.519
  Diabetes                                                        2 (4.4)             2105 (73.5)      0.001
  Inotropic support                                                                                    
  Intravenous inotropes                                          37 (82.2)             2495 (89)       0.547
  1--2 inotropes                                                 26 (57.8)            2149 (76.7)      
  ≥3 inotropes                                                   11 (24.4)            346 (12.3)       
  IABP                                                           7 (15.9)             297 (11.3)       0.342
  ECLS                                                           17 (37.8)            303 (10.5)       \<0.001
  Mechanical ventilation                                         14 (31.1)            406 (15.4)       0.004
  Blood chemistry                                                                                      
  Creatinine (μmol/L)                                          111 (83--123)         111 (85--150)     0.465
  ALAT (U/L)                                                   29 (54--177)           29 (18--70)      0.001
  ASAT (U/L)                                                   135 (31--410)          33 (23--74)      \<0.001
  LDH (U/L)                                                   434 (314--1173)       308 (238--452)     \<0.001
  Total bilirubin (mg/dL)                                    1.78 (0.78--2.26)     1.29 (0.80--2.10)   0.591
  Haemoglobin (g/dL)                                         11.9 (10.3--13.6)     11.8 (10.2--13.5)   0.844
  White blood cell count (× 10^9^/L)                         10.7 (8.9--14.0)       8.4 (6.7--11.0)    \<0.001
  Thrombocytes (× 10^9^/L)                                     173 (80--247)        199 (150--250)     0.030

ALAT, alanine aminotransaminase; ASAT, aspartate transaminase; BMI, body mass index; BSA, body surface area; ECG, electrocardiogram; ECLS, extracorporeal life support; IABP, intra‐aortic balloon pump; ICD, implantable cardioverter‐defibrillator; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LDH, lactate dehydrogenase; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction.

Values are median (inter‐quartile range), mean \[confidence interval\], or *n* (%).

A comparison between patients whose LVAD was explanted and patients with another outcome (ongoing, HTx or death) reveals that recovery patients were significantly younger (45 vs. 53.5 years; *P* \< 0.001), had a shorter duration of cardiac disease (*P* \< 0.001) and less implantable cardioverter‐defibrillators implanted (8.9% vs. 61.4%; *P* \< 0.001), and were more often in INTERMACS Patient Profile 1 (*P* = 0.01; *Table 1B*). Furthermore, the predominant aetiologies of HF were myocarditis and dilated cardiomyopathy for recovery patients, while ischaemic cardiomyopathy was the main cause of HF in the non‐recovery group.

3.2. Perioperative characteristics {#ehf212629-sec-0012}
----------------------------------

The indication designation was BTT in 22 (78.5%), destination therapy in 2 (7.1%), and rescue therapy in 4 (14.3%) (*Table* [2](#ehf212629-tbl-0003){ref-type="table"}). Implanted devices included the HeartMate II (*n* = 14) (Abbott, Lake Bluff, IL, USA), HeartWare HVAD (*n* = 11) (Medtronic, Minneapolis, MN, USA), HeartMate 3 (*n* = 2) (Abbott, Lake Bluff, IL, USA), and one unknown device. Concomitant cardiac surgery was performed in five patients: three patent foramen ovale repairs, one tricuspid valve repair, and one aortic valve replacement. Two patients received a temporary right VAD. Median time in the operating room was 208 min (range: 130--683), with a median CPB time of 75 min (95--147). Post‐operative intensive care unit stay ranged from 4 to 147 days with a median of 17 days and a median hospital stay of 30 days (17--165). Patients with a follow‐up after LVAD explantation had significantly different device strategies (*P* \< 0.001) (less BTR and more BTT patients) and a shorter duration of CPB (*P* = 0.034) compared with patients without a follow‐up.

###### 

Implantation and post‐implantation characteristics for recovery patients

                                             With follow‐up (28)   No follow‐up (17)   *P*‐value
  ----------------------------------------- --------------------- ------------------- -----------
  Device strategy                                                                       \<0.001
  BTT                                            22 (78.5%)            7 (36.9%)      
  DT                                              2 (7.1%)             2 (10.5%)      
  Rescue therapy                                  4 (14.3%)            2 (10.5%)      
  Bridge to recovery                               0 (0%)              8 (42.1%)      
  Device type                                                                            0.204
  HeartMate II                                    14 (50%)             6 (31.6%)      
  HVAD                                           11 (39.3%)            9 (47.4%)      
  HeartMate 3                                     2 (7.1%)              0 (0%)        
  PVAD                                             0 (0%)              2 (10.5%)      
  Other/unknown                                   1 (3.6%)             2 (10.5%)      
  Concomitant cardiac procedures                                                      
  PFO/ASD closure                                 3 (10.7%)            2 (10.5%)      
  Tricuspid repair                                1 (3.6%)             4 (21.1%)      
  Tricuspid replacement                                                1 (5.3%)       
  Aortic repair                                                        1 (5.3%)       
  Aortic valve replacement                        1 (3.6%)                            
  Mitral repair                                                        1 (5.3%)       
  CABG                                                                 1 (5.3%)       
  Concomitant temporary RVAD implantation         2 (7.1%)             2 (10.5%)         1.000
  Time in OR (min)                             208 (130--683)        276 (95--375)       0.600
  Cardiopulmonary bypass time (min)             75 (95--147)         124 (50--235)       0.034
  ICU stay (days)                                17 (4--147)          27 (2--66)         0.377
  Hospital stay (days)                          30 (17--165)         39 (14--144)        0.328

ASD, atrial septal defect; BTT, bridge to transplantation; CABG, coronary artery bypass grafting; DT, destination therapy; ICU, intensive care unit; OR, operating room; PFO, patent foramen ovale; RVAD, right ventricular assist device.

Values are median (range) or *n* (%).

3.3. Outcomes during ventricular assist device support {#ehf212629-sec-0013}
------------------------------------------------------

The median support time of the patients was 410 days (59--1286). Within this time frame, the following key AEs were captured: major infection, major bleeding and device malfunction, and haemolysis (*Table* [3](#ehf212629-tbl-0004){ref-type="table"}). Eight (28.6%) patients remained free of any AEs during LVAD support, while 10 patients (35.7%) encountered three or more AEs. Forty‐eight (73.8%) captured AEs required a hospitalization. There were no significant differences to the patients with missing follow‐up after explantation.

###### 

Time on support and AEs during mechanical circulatory support for recovery patients

                                      With follow‐up (28)   No follow‐up (17)   *P*‐value
  ---------------------------------- --------------------- ------------------- -----------
  Time on support (days)                410 (59--1286)       231 (10--1425)       0.06
  Type of AEs                                                                  
  Major infection                         21 (32.3%)            4 (14.3%)      
  Major bleeding                           8 (12.3%)            1 (3.6%)       
  Device malfunction                       6 (9.2%)             5 (17.9%)      
  Haemolysis                               4 (6.2%)             2 (7.1%)       
  Cardiac arrhythmia                       3 (4.6%)             1 (3.6%)       
  Stroke                                   2 (3.1%)             3 (10.7%)      
  Renal dysfunction                        2 (3.1%)             4 (14.3%)      
  Right heart failure                       0 (0%)              1 (3.6%)       
  Other                                   19 (29.2%)             7 (25%)       
  Number of AEs per patient                                                       0.889
  0                                        8 (28.6%)            5 (29.4%)      
  1--2                                    10 (35.7%)            8 (47.1%)      
  3--4                                     7 (25.0%)            3 (17.6%)      
  ≥5                                       3 (10.7%)            1 (5.9%)       
  Hospitalizations required for AE        48 (73.8%)           26 (92.9%)      
  Hospitalizations per patient                                                    1.000
  0                                       10 (35.7%)            6 (35.3%)      
  1--2                                    11 (39.3%)            7 (41.2%)      
  3--4                                     5 (17.9%)            3 (17.6%)      
  ≥5                                       2 (7.1%)             1 (5.9%)       

AE, adverse event.

Values are median (range) or *n* (%).

3.4. Outcomes after left ventricular assist device explantation {#ehf212629-sec-0014}
---------------------------------------------------------------

Median follow‐up time after LVAD explantation is 26 months (0.3--73). Freedom from death, LVAD reimplantation, HTx, and relapse of HF ≥ NYHA III was 100% at 30 days and 88% at 24 months after explantation (*Figure* [*1*](#ehf212629-fig-0001){ref-type="fig"} and *Table* [4](#ehf212629-tbl-0005){ref-type="table"}). Two patients encountered an HF relapse, which is in part attributable to new onset of degenerative mitral regurgitation in one patient. One patient required reimplantation of an LVAD after 32 days. Finally, one patient died 302 days after LVAD explantation due to sepsis. Until 48 months, this percentage remained unchanged (88%); however, follow‐up was only available for six patients for this duration of follow‐up.

![Freedom of death, left ventricular assist device reimplantation, heart transplantation (HTx), and significant heart failure (HF) relapse after left ventricular assist device explantation.](EHF2-7-1085-g001){#ehf212629-fig-0001}

###### 

Long‐term outcome post‐LVAD explant for recovery patients

  --------------------------------------- ---------------------
  Follow‐up time (months)                     26 (0.3--73)
  Primary outcome                         
  Ongoing after explant                        26 (92.8%)
  HF recurrence                                 3 (10.7%)
  LVAD reimplantation                           1 (3.6%)
  Death                                         1 (3.6%)
  BMI(kg/m^2^)                             27.6 \[25.4--29.7\]
  Blood pressure (mmHg)                   
  Systolic                                    113 (88--160)
  Diastolic                                    77 (51--98)
  Mean arterial pressure                      90 (68--113)
  Echocardiography data                   
  LVEF (%)                                     40 (15--60)
  LVEDD (mm)                                   54 (41--74)
  LVESD (mm)                                   43 (27--63)
  MR grade ≥3                                       2
  ECG                                     
  Heart rate (b.p.m.)                         73 (48--105)
  Rhythm                                  
  Sinus                                         21 (75%)
  Atrial fibrillation/flutter                   3 (10.7%)
  Other                                         4 (14.3%)
  QRS width (ms)                              98 (74--188)
  QTc duration (ms)                          435 (374--593)
  Blood chemistry                         
  Creatinine (μmol/L)                         97 (62--248)
  Bilirubin (mg/dL)                          0.6 (0.3--2.8)
  Functional status at last follow‐up     
  NYHA Class I                                   7 (25%)
  NYHA Class II                                16 (57.2%)
  NYHA Class III                                3 (10.7%)
  Unknown                                       2 (7.1%)
  HF medication                           
  Beta‐blockers                                24 (85.7%)
  ACE inhibitors                               20 (71.4%)
  Loop diuretics                                14 (50%)
  Inflow cannula *in situ*                      3 (10.7%)
  Anticoagulation/anti‐platelet therapy        20 (71.4%)
  Acetylsalicylic acid                         12 (42.9%)
  Vitamin K antagonist                         11 (39.3%)
  Both                                          4 (14.3%)
  None                                           8 (29%)
  Number of patients with CVA                    0 (0%)
  --------------------------------------- ---------------------

ACE, angiotensin‐converting enzyme; BMI, body mass index; CVA, cerebrovascular accident; ECG, electrocardiogram; HF, heart failure; LVAD, left ventricular assist device; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end‐systolic diameter; MR, mitral regurgitation; NYHA, New York Heart Association.

Values are median (range), mean \[standard deviation\], or *n* (%).

Median LVEF at last follow‐up is 40% (15--60), with a median left ventricular end‐diastolic and end‐systolic diameter of 54 mm (41--74) and 43 mm (27--63), respectively. Patient\'s HF symptoms are predominantly NYHA I and II (82.2%) with three patients suffering significant HF symptoms (NYHA III). All patients were on at least one type of HF medication: with beta‐blockers in 24/28 (85.7%) and angiotensin‐converting enzyme inhibitors in 20/28 patients (71.4%) being used most frequently.

The inflow cannula remained *in situ* after explantation in three patients (11%). Of these patients, two were on both warfarin and aspirin and one patient only used warfarin. The inflow cannula was not *in situ* in the 25 other patients, two of them used both warfarin and aspirin. Long‐term anticoagulation treatment was aspirin in 43% of the patients, while in 39%, warfarin was used. Four patients were prescribed with both aspirin and warfarin. In eight (29%) patients, no anti‐platelet or anticoagulation therapy was used. No cerebrovascular accident was reported in any patient.

4. Discussion {#ehf212629-sec-0015}
=============

This study provides a multi‐centre, mid‐ to long‐term follow‐up of patients whose LVAD was explanted because of myocardial recovery. The mid‐ to long‐term outcomes appear to be encouraging with 88% of the patients surviving without HTx, LVAD reimplantation, or relapse of HF at 24 months of follow‐up. Furthermore, the majority of patients suffered from mild HF‐symptoms only (NYHA Class I--II). The number of patients with sufficient myocardial recovery for LVAD explantation is comparable with other registries such as INTERMACS, which reported a successful weaning rate of approximately 1% in the latest annual report.[10](#ehf212629-bib-0010){ref-type="ref"}, [11](#ehf212629-bib-0011){ref-type="ref"}

A comprehensive review of single‐centre studies reporting on myocardial recovery allowing LVAD explantation found weaning rates ranging from 4.5% to 63% and thus contrasts with lower recovery rates reported in the INTERMACS or EUROMACS registries.[12](#ehf212629-bib-0012){ref-type="ref"} Some of these studies have reported higher rates of successful weaning. Interestingly, some showed a successful explantation rate of 12 in 19 (63%) patients supported by a HeartMate II.[13](#ehf212629-bib-0013){ref-type="ref"} However, this population was young (mean age 35.2 years) and patients with ischaemic heart disease were excluded. Moreover, they received aggressive pharmacotherapy with maximum HF medication combined with clenbuterol (β~2~‐agonist).

These high rates of recovery may partly be explained because of the commitment of some centres resulting in specific clinical and scientific focus on the recovery. This might result in advanced, aggressive strategies to identify potential patients eligible for LVAD explantation and thus treating those patients with targeted and strictly regulated HF medication. Furthermore, studies that included patients with non‐ischaemic heart disease as aetiology of HF and patients with recent onset of HF tend to have higher rates of successful myocardial recovery. These observations correspond well with our study in which the majority of patients had their first cardiac disease diagnosis less than 1 year ago and ischaemic cardiomyopathy represented an uncommon aetiology of HF. Indeed, the baseline characteristics that are significantly different in patients with LVAD explantation are very similar to the variables used in the INTERMACS Cardiac Recovery Score of Wever‐Pinzon *et al*.[11](#ehf212629-bib-0011){ref-type="ref"}

In the literature, several case series and small cohort studies report on patients having recovery of left ventricle (LV) function that allowed LVAD explantation. Studies such as Dandel *et al*.[4](#ehf212629-bib-0004){ref-type="ref"} report that LVAD (Novacor) explantation was successful in 32 of 131 patients with idiopathic dilated cardiomyopathy, with a 5 year survival of 78.3% and 31.1% HF recurrence rate in 3 years, after being supported with an LVAD for a mean duration of 4.6 months (SD ± 4.4). Birks *et al*.[5](#ehf212629-bib-0005){ref-type="ref"} reported that out of 15 patients with severe HF due to non‐ischaemic cardiomyopathy, 11 had LVAD explantation after a mean of 320 days of LVAD support; 88.9% of the surviving patients were free from HF at 4 years after explantation. Another study showed that survival after explantation of HeartMate II was 83.3% after 3 year follow‐up.[13](#ehf212629-bib-0013){ref-type="ref"} A study of 14 patients revealed that after a mean follow‐up time of 3.6 years (±1.9) after explantation, no patient had died and had a functional NYHA class of I.[6](#ehf212629-bib-0006){ref-type="ref"} Frazier *et al*.[7](#ehf212629-bib-0007){ref-type="ref"} achieved explantation in 27 patients out 657 patients supported by an LVAD, with 25 of them surviving after a mean follow‐up of 3.2 years (±2.6) all of them with NYHA Class I with medical therapy. In comparison, we showed a similar excellent survival of 88% without HTx, LVAD reimplantation or significant HF relapse in a European multi‐centre registry, with the majority of patients only suffering from mild HF symptoms after explantation. This highlights that, in carefully selected patients, excellent results can be achieved after LVAD explantation and are not restricted to one centre.

4.1. Pathophysiology and clinical implications of left ventricular recovery {#ehf212629-sec-0016}
---------------------------------------------------------------------------

The pathophysiology of HF is complex and multifactorial. Systolic HF is accompanied by LV remodelling, which is characterized by three categories of changes in the heart: myocyte defects, myocardial defects, and abnormal LV geometry.[14](#ehf212629-bib-0014){ref-type="ref"} In contrast, to achieve myocardial recovery, the heart has to undergo cardiac reverse remodelling. Support by cf‐LVADs results in left ventricular pressure and volume unloading as well as increased cardiac output[15](#ehf212629-bib-0015){ref-type="ref"}, [16](#ehf212629-bib-0016){ref-type="ref"} and has shown to promote certain forms of reverse remodelling[17](#ehf212629-bib-0017){ref-type="ref"}: reduction of cardiac myocyte hypertrophy,[18](#ehf212629-bib-0018){ref-type="ref"}, [19](#ehf212629-bib-0019){ref-type="ref"} changes in gene expression,[20](#ehf212629-bib-0020){ref-type="ref"}, [21](#ehf212629-bib-0021){ref-type="ref"} and normalization of β‐adrenergic receptor and inotropic responsiveness.[22](#ehf212629-bib-0022){ref-type="ref"} Concerning restoration of the extracellular matrix, conflicting studies exist, with some studies reporting an increase in total extracellular matrix collagen,[23](#ehf212629-bib-0023){ref-type="ref"}, [24](#ehf212629-bib-0024){ref-type="ref"} while others report a decrease.[25](#ehf212629-bib-0025){ref-type="ref"} Finally, studies have shown an improvement in cardiac myocyte contractility after LVAD implantation.[26](#ehf212629-bib-0026){ref-type="ref"}, [27](#ehf212629-bib-0027){ref-type="ref"} There are some excellent reviews covering this topic in much more detail.[14](#ehf212629-bib-0014){ref-type="ref"}, [28](#ehf212629-bib-0028){ref-type="ref"} On the clinical side, the criteria used for the decision of LVAD explantation differ between centres.[8](#ehf212629-bib-0008){ref-type="ref"}, [13](#ehf212629-bib-0013){ref-type="ref"}, [29](#ehf212629-bib-0029){ref-type="ref"} Clinical parameters that indicate LV remodelling and might indicate myocardial recovery often include an increase in LVEF, decreases in end‐diastolic left ventricular diameter, (partial) reversal of functional mitral regurgitation, normalization of cardiac filling pressures, and cardiac sinus rhythm with a normal heart rate. Unfortunately, studies linking pathophysiological findings with these clinical outcomes are scarce.

4.2. Future perspectives {#ehf212629-sec-0017}
------------------------

A combination of clinical and biological findings for patients undergoing LVAD implantation is currently lacking robust data with both studies conducted separately of each other. Preferably, one would collect histological/biological data and clinical data before LVAD implantation, during LVAD support, and after explantation (if applicable). This holistic approach would provide much needed insight in the changes that are induced by VAD therapy and would enable us to link and understand pathophysiological changes to clinical changes and vice versa.

Finally, because the number of patients that have sufficient myocardial recovery to enable LVAD explantation is limited, it is critical that researchers and clinicians cooperate in large registries such as EUROMACS and INTERMACS, by adding data fields for centres willing to capture data on the follow‐up of these patients. As a consequence, the EUROMACS board set out the goal that follow‐up of after explantation of VAD devices due to recovery should also be captured in the near future.

4.3. Limitations {#ehf212629-sec-0018}
----------------

This study has certain limitations that should be considered while interpreting the results. Data were gathered retrospectively, and the number of data fields captured is limited. Furthermore, it is possible that not all patients whose LVAD was explanted because of recovery were captured in the EUROMACS registry. It is also possible that the follow‐up of patients who actually have been explanted because of recovery has not been registered yet. This might result in a relative underestimation of the number of patients with myocardial recovery; however, the EUROMACS registry regularly checks and audits participating centres for data quality and completion. Finally, we only received follow‐up data on 62% of those patients weaned from LVAD support, which may constitute a potential selection bias resulting in favourable outcomes. However, the baseline characteristics and follow‐up during LVAD support of patients with and without follow‐up were, apart from one variable, not significantly different (*Table* [1](#ehf212629-tbl-0001){ref-type="table"} *A*).

5. Conclusions {#ehf212629-sec-0019}
==============

To our knowledge, this is one of the first multi‐centre studies to review midterm to long‐term follow‐up after LVAD explantation due to myocardial recovery. Although LVAD explantation remains rare, outcomes after explantation are excellent with a majority of patients ongoing without HTx or LVAD reimplantation while having limited HF symptoms only. Large, prospective registries and/or studies are required to generate pertinent data in order to better understand this challenging population.
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